Pfizer (NYSE:PFE) Shares Down 1.9% – Time to Sell?

Pfizer Inc. (NYSE:PFE) shares traded down 1.9% on Wednesday . The company traded as low as $26.74 and last traded at $26.78. 35,112,334 shares traded hands during trading, a decline of 19% from the average session volume of 43,121,742 shares. The stock had previously closed at $27.31.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Seagen acquisition beginning to pay off — coverage notes Pfizer’s $43B Seagen deal is giving it a dominant position in the Antibody‑Drug Conjugate (ADC) market, strengthening its oncology growth runway beyond legacy products. This supports longer‑term revenue diversification. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: Dividend reaffirmed — Pfizer’s board declared a $0.43 quarterly dividend (payable June 12; record date May 8). The steady, high yield (roughly in the mid‑single digits) supports income investor demand and can act as a valuation floor. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Pipeline progress and obesity/GLP‑1 push — Pfizer reported Phase 2b results and is advancing a monthly GLP‑1 obesity program (PF‑08653944) and several early‑stage studies (heart failure, liver, new Phase 1 cancer trial), adding meaningful optionality to future growth. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Neutral Sentiment: Shareholder meeting results released — Pfizer posted 2026 shareholder meeting outcomes; no major governance surprises were reported, so minimal immediate market impact. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Eliquis distribution move — Pfizer and Bristol Myers will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27, which may expand access and volume but could compress pricing/margins; likely mixed to neutral near‑term. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban’s online pharmacy
• Negative Sentiment: Trial termination trims oncology pipeline — Pfizer ended an early‑stage cancer trial, signaling a pullback for that specific program and reducing near‑term upside from that asset. This is a discrete negative for pipeline expectations. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism and sell ratings persist — Barclays reiterated a sell and some coverage favors peers (e.g., Merck) on valuation and dividend tradeoffs, which can cap multiple expansion and weigh on sentiment. Barclays Remains a Sell on Pfizer (PFE)

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Guggenheim boosted their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. TD Cowen restated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.48.

Pfizer Price Performance

The company has a market capitalization of $153.56 billion, a P/E ratio of 19.86 and a beta of 0.43. The company’s 50-day moving average price is $27.24 and its two-hundred day moving average price is $26.06. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s dividend payout ratio is presently 126.47%.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently modified their holdings of PFE. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank grew its stake in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. grew its stake in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC grew its stake in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.